Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7757786 | 1.00 | HDAC1 (0.52) | HDAC1HDAC2ALDH1A1GAAKDM4E | |
| SCHEMBL3803230 | 1.00 | HDAC1 (0.52) | HDAC1HDAC2ALDH1A1GAAKDM4E | |
| Hydrochloric Acid SCHEMBL8457836 | 0.98 | HDAC1 (0.51) | HDAC1HDAC2ALDH1A1GAAKDM4E | |
| Hydrochloric Acid SCHEMBL8457834 | 0.98 | HDAC1 (0.51) | HDAC1HDAC2ALDH1A1GAAKDM4E | |
| SCHEMBL6015376 | 0.98 | HDAC1 (0.51) | HDAC1HDAC2ALDH1A1GAAKDM4E | |
| SCHEMBL6015374 | 0.98 | HDAC1 (0.51) | HDAC1HDAC2ALDH1A1GAAKDM4E | |
| SCHEMBL14619953 | 0.85 | HDAC1 (0.52) | HDAC1HDAC2ALDH1A1GAAKDM4E | |
| SCHEMBL14587959 | 0.81 | HDAC1 (0.49) | HDAC1HDAC2 | |
| SCHEMBL2154529 | 0.81 | HDAC1 (0.52) | HDAC1HDAC2ALDH1A1GAAKDM4E | |
| SCHEMBL15328886 | 0.81 | HDAC1 (0.49) | HDAC1HDAC2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0773782-B1 | TERPENOIDIC DERIVATIVES (SARCODICTYINS) USEFUL AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN SPA (IT) | 2001-03-14 | — | — | EP | claimed |
| US-5869514-A | ADMINISTERING SARCODICTYINS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-02-09 | — | — | US | claimed |
| EP-0773782-A1 | TERPENOIDIC DERIVATIVES (SARCODICTYINS) USEFUL AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-05-21 | — | — | EP | claimed |
| WO-1996036335-A1 | TERPENOIDIC DERIVATIVES (SARCODICTYINS) USEFUL AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 1996-11-21 | — | — | WO | claimed |
| CN-117683049-A | Indole derivatives as RAS inhibitors for the treatment of cancer | 锐新医药公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4214209-A1 | INDOLE DERIVATIVES AS RAS INHIBITORS IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| CN-116457358-A | Indole derivatives as RAS inhibitors for the treatment of cancer | 锐新医药公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4208261-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-116209438-A | Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors | 锐新医药公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-3670539-A1 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | Daiichi Sankyo Europe GmbH (DE) | 2020-06-24 | — | — | EP | disclosed |
| WO-2003024529-A1 | SIMPLIFIED SARCODICTYN DERIVATIVES AS ANTI-TUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2003-03-27 | — | — | WO | disclosed |
| EP-0773782-B1 | TERPENOIDIC DERIVATIVES (SARCODICTYINS) USEFUL AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN SPA (IT) | 2001-03-14 | — | — | EP | disclosed |
| US-6172205-B1 | DEHALOGENATION, ACID CATALYSIS, CYCLIZATION, RING CONTRACTION; ANTICARCINOGENIC AGENTS | THE TRUSTEES OF COLUMBIA IN THE CITY OF NEW YORK | 2001-01-09 | — | — | US | disclosed |
| EP-0993457-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-19 | — | — | EP | disclosed |
| US-5922750-A | SARCODICTYINS FOR TREATMENT OF CANCER | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-07-13 | — | — | US | disclosed |
| WO-1998057954-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-23 | — | — | WO | disclosed |
| EP-0773782-A1 | TERPENOIDIC DERIVATIVES (SARCODICTYINS) USEFUL AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996036335-A1 | TERPENOIDIC DERIVATIVES (SARCODICTYINS) USEFUL AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690915-B2 | Ras inhibitors | KRAS, NRAS, HRAS | HDAC1 1804/4885HDAC2 3087/4885ALDH1A1 4437/4885 |
| US-20230226186-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HDAC1 1804/4885HDAC2 3087/4885ALDH1A1 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.